|
Synonyms: APN-311 | Ch14.18 | MAb-14.18 | Unituxin®
dinutuximab is an approved drug (FDA (2015))
Compound class:
Antibody
Comment: Dinutuximab is a chimeric mouse/human monoclonal antibody targeting ganglioside-GD2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A patent search identifies US20140170155 [4] as the applicable patent. US20140170155 reveals APN311 as a formulation of the mouse-human chimeric anti-GD2 antibody ch14.18 recombinantly produced in Chinese hamster ovary (CHO) cells. Efficacy of the preferred antibody was determined by its cytolysis capacity in GD2-expressing cells, as determined by a complement dependent cytolysis assay. |
| Bioactivity Comments |
| A binding affinity value is not presented in the associated patent US 20140170155 [4]. Soman et al (2012) [6] report an affinity (Kd) for FcγRIIIA binding by dinutuximab of approximately 500nM, measured using BIACore surface plasmon resonance methodology. Fcγ binding is a measure of the antibody's ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC). A Ka for the originally identified murine anti-GD2 antibody 14.18 is provided by Mujoo et al (1987) [5]. Converting this to a Kd gives a value of 0.03nM which is an approximation of the binding affinity of the chimeric human (ch14.18) antibody that is dinutuximab.. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
